Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) 抗体 (ab5473)

製品の概要

  • 製品名Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody
    VEGF Receptor 2 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to VEGF Receptor 2 (phospho Y1054 + Y1059)
  • 特異性VEGFR 3 (100% homologous) has not been tested but is expected to react.
  • アプリケーション適用あり: IHC-P, WBmore details
  • 種交差性
    交差種: Mouse, Rat, Human
  • 免疫原

    Synthetic phospho peptide (Human)containing Tyrosines 1054 and 1059. This sequence is conserved in mouse and rat.

  • ポジティブ・コントロール
    • Porcine aortic endothelial cells transfected with a chimeric receptor consisting of the extracellular portion of the CSF 1 receptor fused with the transmembrane and intracellular domains of mouse VEGFR 2.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab5473 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
IHC-P Use at an assay dependent concentration. PubMed: 20566746
WB Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 200 kDa.

ターゲット情報

  • 機能Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • 関連疾患Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • 配列類似性Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • 翻訳後修飾Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • 細胞内局在Membrane.
  • Information by UniProt
  • 参照データベース
  • 別名
    • CD309 antibody
    • CD309 antigen antibody
    • EC 2.7.10.1 antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • Kdr antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody 画像

  • Peptide Competition and Stimulation: Extracts prepared from PAE cells transfected with a chimeric receptor (see Positive Controls section above for full description) were left unstimulated (1, 2) or stimulated with VEGF (3-8), then were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4°C, then were incubated with a VEGFR2 pan antibody (1, 3) or 0.50 µg/mL VEGFR2 ab5473 antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (2, 4, 5), the non-phosphopeptide corresponding to the immunogen (6), a generic phosphotyrosine containing peptide (7), or, the phosphopeptide immunogen (8). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5473 blocks the antibody signal,

Anti-VEGF Receptor 2 (phospho Y1054 + Y1059) antibody (ab5473) 使用論文

This product has been referenced in:
  • Reeson P  et al. Delayed inhibition of VEGF signaling after stroke attenuates blood-brain barrier breakdown and improves functional recovery in a comorbidity-dependent manner. J Neurosci 35:5128-43 (2015). WB ; Mouse . Read more (PubMed: 25834040) »
  • Dai J  et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 20:617-30 (2014). Human . Read more (PubMed: 24097861) »

See all 10 Publications for this product

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 1% · Temperature: 25°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: citrate bufer
Sample Rat Tissue sections (rat bone marrow tissue)
Specification rat bone marrow tissue
Permeabilization No
Fixative Formaldehyde
Username

Abcam user community

Verified customer

投稿 Mar 07 2014

Thank you for contacting Abcam regarding expiration dates of our products.

At Abcam, we guarantee the effectiveness of our products for a period of 6 months from date of delivery. Should you experience any issues using one of our products in...

Read More

Thank you for your enquiry. I can confirm that the immunogen sequence used to generate this polyclonal antibody was the dual phosphorylated form of VEGF receptor 2. (pYpY1054/1057). Because of the nature of polyclonal antibodies , it is potentially...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"